Trade Summary

Today, Blum Robert I, serving as Pres, CEO at Cytokinetics Inc (CYTK), sold 7,500 shares at $77.92 per share, for a total transaction value of $584,400.00. Following this transaction, Blum Robert I now holds 404,496 shares of CYTK.

This sale represents a 2.00% decrease in Blum Robert I's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Thursday, May 14, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, May 14, 2026 at 4:26 PM ET, meaning the disclosure happened on the same day as the trade.

Cytokinetics Inc operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.